Jan 1970
Protected: Plex Platform Pipeline new
This content is password protected. To view it please enter your password below: Password:
Read more >
This content is password protected. To view it please enter your password below: Password:
Read more >This content is password protected. To view it please enter your password below: Password:
Read more >CONSISTENT CLINICAL RESULTS DEMONSTRATED ACROSS TRIALS POLYPID'S PHASE 3 CLINICAL TRIALS: D-PLEX100 – 311 – ( NCT04233424 ) – Abdominal / Colorectal surgery Efficacy and Safety of D-PLEX in the Prevention of Abdominal Surgery Incision Infection Post Colorectal Surgery. Phase III, Prospective, Multinational, Multicenter, Randomized, Controlled, Two-arm, Double Blind Study to assess Efficacy and Safety of…
Read more >CHASING ZERO: THE DRIVE TO ELIMINATE SURGICAL SITE INFECTIONSSSIs remain a substantial cause of morbidity, prolonged hospitalization, and death. SSI are the second most common hospital acquired infections in United States and the European Union and occur in approximately 2% to 5% of patients undergoing inpatient surgery worldwide 1. The incidence of SSI is doubled…
Read more >TREATMENT OF PERI-IMPLANTITIS - ONE OF THE MOST CHALLENGING Biofilm Metal Implant Chronic Infection Constant Contamination Mix Bacterial Makeup Primary efficacy endpoint: D-PLEX500 reduces Probe Pocket depth (PPD) vs. SoCD-PLEX500 prevented the loss of implants
Read more >Another product candidate from the PLEX-doxycycline family, for use in connection with orthopedic surgeries for the prevention of SSIs and support of bone recovery. [siteorigin_widget class="video_Widget"][/siteorigin_widget] D-PLEX1000 Showed Effective Treatment of Orthopedic Surgeries No deep bone infections after 6 months across 24 treated patients, in comparison with reported incidences in the literature ranging between 7%…
Read more >D-PLEX100 – PHASE 2 - SIGNIFICANT DECREASE IN THE RATE OF SSI IN ABDOMINAL SURGERIES Design: accessor and patient blinded and double-arm randomized study Objective: safety and efficacy of D-PLEX100 + SoC (n=101) vs. SoC alone (n=100) in prevention of incision infection post-colorectal surgery Primary efficacy end-point: the decrease of infection rate as measured by…
Read more >PolyPid’s ongoing clinical trials: D-PLEX100 – 301 – (NCT02731573) - Completed Initial Safety and Efficacy of D-PLEX100 in the Prevention of Primary Sternal Infection Post Cardiac Surgery. For more information, please visit clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02731573?term=D-PLEX&rank=1 D-PLEX100 – 302 – (NCT03558984) Efficacy and Safety of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery For more information, please…
Read more >OUR PIPELINE IS DESIGNED TO ADDRESS DISEASES WITH HIGH UNMET MEDICAL NEEDS We paired our technology with drugs already approved by the U.S. FDA or innovative drug candidates POLYPID'S PHASE 3 CLINICAL TRIALS: SHIELD I ( NCT04233424 ) – Abdominal / Colorectal surgery Efficacy and Safety of D-PLEX100 in the Prevention of Abdominal Surgery Incision…
Read more >LOCALIZED DRUG DELIVERY SYSTEM STUDIED FOR PREVENTION OF SSIs Active Ingredient: Doxycycline (broad-spectrum antibiotic) Release Duration: Prolonged effect of 30 days Indication: Prevention of abdominal incisional surgical site infection (SSI) Release profile: No burst, constant & linear release Dosing: Varies by incision size 1vial < 10cm, 10cm < 2vials > 20cm, 3 vials >20cm Negligible…
Read more >
PolyPid’s PLEX targeted drug delivery platform enables localized, controlled, continuous release of medication over prolonged periods of time for better patient outcomes.
Read More >
Is designed to prevent the risk of surgical site infections in both bone and soft tissue through its cutting-edge, local, extended-release mechanism
Read More >
Comprised of antibiotic eluting ß tri-calcium phosphate (ßTCP) granules, designed for bone related infections applications.
Read More >